Nivolumab-associated IgA Nephropathy in a Child With Malignant Melanoma
Authors:
- 25 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 46 (7) , e534-e536
Abstract
Immune checkpoint inhibitors are humanized antibodies that inhibit downregulatory receptors on T cells, enhancing the antitumor activity of these cells. However, they have been associated with a wide range of systemic immune-related adverse events, including renal toxicities, among others. Most renal immune-related adverse events are acute interstitial nephritis causing acute kidney injury. Recently, immune checkpoint inhibitors-associated glomerular diseases, including IgA nephropathy, have been reported in adults. Most of the adult cases with glomerular involvement had also concomitant acute interstitial nephritis and acute kidney injury. We present the first pediatric case of IgA nephropathy without acute kidney injury during nivolumab treatment.Keywords
This publication has 17 references indexed in Scilit:
- Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?Renal Failure, 2022
- A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular DiseaseKidney International Reports, 2021
- Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancerMedicine, 2020
- Immune checkpoint inhibitors: recent progress and potential biomarkersExperimental & Molecular Medicine, 2018
- Epidemiology of IgA Nephropathy: A Global PerspectiveSeminars in Nephrology, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsKidney International, 2016
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialThe Lancet Oncology, 2015
- Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 BlockadeSeminars in Oncology, 2010